Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments.

ABSTRACT:

Background

Spinal muscular atrophy (SMA) is a rare and devastating condition for which new disease-modifying treatments have recently been approved. Given the increasing importance of economic considerations in healthcare decision-making, this review summarizes the studies assessing the cost of SMA and economic evaluations of treatments. A systematic review of the literature in PubMed and Scopus up to 15 September 2020 was conducted according to PRISMA guidelines.

Results

Nine studies reporting the annual cost of care of patients with SMA and six evaluations of the cost-effectiveness of SMA treatments were identified. The average annual cost of SMA1, the most frequent and severe form in which symptoms appear before the age of 6 months were similar according to the different

SUBMITTER: Dangouloff T 

PROVIDER: S-EPMC7824917 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature